Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Extension Study of Mavrilimumab in Rheumatoid Arthritis
2011-005648-93Phase 2Completed
- Sponsor
- MedImmune
- Start
- Apr 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mavrilimumab in rheumatoid arthritis (RA), sponsored by MedImmune. Primary endpoint: Long-term safety of mavrilimumab. Started Apr 2012; status: completed.
02
Drugs
mavrilimumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2011-005648-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005648-93.